Skip to main content
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 2003 Apr 15;111(8):1259. doi: 10.1172/JCI200315598A

Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice

Scott P Heximer, Russell H Knutsen, Xiaoguang Sun, Kevin M Kaltenbronn, Man-Hee Rhee, Ning Peng, Antonio Oliveira-dos-Santos, Josef M Penninger, Anthony J Muslin, Thomas H Steinberg, J Michael Wyss, Robert P Mecham, Kendall J Blumer
PMCID: PMC152949  PMID: 12697745

Original citation: J. Clin. Invest. 111:445–452 (2003). doi:10.1172/JCI200315598.

The authors wish to add the following information.

Table 1: The doses of antagonists used to treat wild-type and RGS2-knockout mice were hexamethonium at 5 mg/kg i.v., prazosin at 200 μg/kg i.v., and candesartan at 100 μg/kg i.v. Effective ganglionic blockade by hexamethonium was established as described previously, whereas blockade by prazosin or candesartan was demonstrated by the inability of a subsequent infusion of phenylephrine (10 μg/kg i.v.) or angiotensin II (1 μg/kg i.v.) to increase blood pressure of wild-type or RGS2-knockout mice.

Figure 3: Blood pressure responses were determined using anesthetized mice as described in Methods. In Figure 3a, the doses of vasoconstrictors used to treat wild-type and RGS2-knockout mice were 1 μg/kg i.v. for angiotensin II and 10 μg/kg i.v. for phenylephrine. These doses were determined empirically, as were those that elicited a near-maximal (>75%) increase in blood pressure (determined by dose-response experiments such as those shown in Figure 4a for phenylephrine). In Figure 3b, candesartan (100 μg/kg i.v.) was infused into wild-type and RGS2-knockout mice over a period of 10 seconds, after which blood pressure was recorded continuously over the time period indicated. In Figure 3c, the same dose of angiotensin II (1 μg/kg iv) was used to treat wild-type and RGS2-knockout mice in order to increase systolic blood pressure to similar absolute levels (160-170 mmHg) prior to antagonist infusion (candesartan, 100 μg/kg i.v.). This approach was established by the results shown in Figure 3a, in which MAP of wild-type mice increased from a resting value (prior to agonist infusion) of ∼85 mmHg to a value of ∼135 mmHg after angiotensin II infusion, and the MAP of RGS2-knockout mice increased from a resting value of ∼135 mmHg to ∼140 mmHg by the same treatment. After a maximal effect of angiotensin II on blood pressure was achieved (∼1 minute), candesartan (100 μg/kg i.v.) was infused over 10 seconds, and decreases in blood pressure were recorded continuously over the time period indicated.


Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES